Reorganization at key client Halozyme will not hit revenues says Avid Bioservices, which predicts ongoing facility revamp and expanding customer base to drive growth in the rest of FY2020. Halozyme Therapeutics recently said it would focus on its Enhanze delivery technology after HALO-301 – its candidate pancreatic cancer drug – fell short in Phase III trials. The San Diego biotech will close its oncology operations and reduce its headcount by approximately 55%, or approximately 160 positions. (Read Xconomy’s report here).…

AGC Bio’s expanded offering at its site in Heidelberg will serve a plasmid DNA (pDNA) space growing at 20 % CAGR, the CDMO says. Contract development manufacturing organization (CDMO) AGC Bio has completed a pDNA manufacturing process improvement project at its site in Heidelberg, Germany. The firm says this will enable the extension of the offer in hosts and plasmids with scales of 1 L to 10 L for High Quality pDNA, and will be easy to scale up to…